Maker of drug to reset gut hormones gets $150M round

Carmot Therapeutics Inc., a Berkeley-based drug developer working on ways to reset gut hormones to tackle obesity and diabetes, raised $150 million in a Series E round, the company said Thursday. The financing was led by Deep Track Capital and included a mix of new investors such as crossover investors Franklin Templeton, Janus Henderson Investors, Millennium Management and TCGX as well as 5AM Ventures and Venrock Healthcare Capital Partners. Existing investors RA Capital Management, The Column …
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news